Abstract 437: Computational discovery and preclinical validation of therapeutic leads with novel MOAs for Glioblastoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-437
Abstract: Glioblastoma (GBM) is an aggressive, highly invasive tumor that has a 5-year survival rate of less than 5%, with median survival of approximately 15 months. Treatment options for patients with GBM are relatively unchanged over… read more here.
Keywords: kinase; inhibitor; inhibitor positive; novel moas ... See more keywords
The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice.
Sign Up to like & getrecommendations! Published in 2023 at "Haematologica"
DOI: 10.3324/haematol.2022.281895
Abstract: Neutralizing anti-factor VIII (FVIII) antibodies, known as FVIII inhibitors, represent a major drawback of replacement therapy in persons with congenital hemophilia A (PwHA), rendering further infusions of FVIII ineffective. FVIII inhibitors can also appear in… read more here.
Keywords: fviii; imlifidase; inhibitor positive; fviii inhibitors ... See more keywords